Category - Developments

Developments

Theratechnologies reduces R&D headcount on sales shortfall

With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...

July 12, 2023

Developments

Synlogic gets FDA fast track to treat phenylketonuria

The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...

July 11, 2023

Developments

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...

July 11, 2023

Developments

MAIA updates survival data from Phase 2 NSCLC trial

MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced...

July 10, 2023

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

Developments

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Vaxart (NASDAQ:VXRT) reported positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Norovirus is the leading cause of acute viral gastroenteritis in...

July 7, 2023

Developments

Revive oral Bucillamine flunks Phase 3 COVID-19 study

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV) reported that its Phase 3 clinical study evaluating the safety and efficacy of oral Bucillamine in patients with mild- to-moderate COVID-19 did not achieve statistical...

July 6, 2023

Developments

ASLAN posts positive Phase 2b results in atopic dermatitis

ASLAN Pharmaceuticals (NASDAQ:ASLN) reported positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, which is often referred to as eczema...

July 6, 2023

Developments

FDA clears protocol for Acasti Phase 3 trial in aSAH

Acasti Pharma (NASDAQ:ACST) and the FDA agreed on the protocol of a Phase 3 trial of GTX-104 in patients with aneurysmal subarachnoid hemorrhage (aSAH), a rare disease with bleeding over the surface of the brain in the...

July 5, 2023

Developments

Palisade Bio completes enrollment in dose optimization study

Palisade Bio (NASDAQ:PALI) completed patient enrollment in its dose optimization study of LB1148, a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal...

July 5, 2023

Category - Developments

Theratechnologies reduces R&D headcount on sales shortfall

Synlogic gets FDA fast track to treat phenylketonuria

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

MAIA updates survival data from Phase 2 NSCLC trial

ZyVersa receives European patent for VAR 200 in kidney disease

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Revive oral Bucillamine flunks Phase 3 COVID-19 study

ASLAN posts positive Phase 2b results in atopic dermatitis

FDA clears protocol for Acasti Phase 3 trial in aSAH

Palisade Bio completes enrollment in dose optimization study

General

More